Navigation Links
MedinCell to Explore Controlled-Release Drug Delivery Partnerships at the World Animal Health Congress
Date:12/2/2011

SAN DIEGO and MONTPELLIER, France, Dec. 2, 2011 /PRNewswire/ -- MedinCell, a leading developer of low-cost, controlled-release drug delivery technology, will be exploring partnerships for key companion and food animal markets with industry leaders at the Terrapinn World Animal Health Congress in Kansas City (December 6-8, 2011).

"MedinCell's biodegradable polymer technology offers exceptional control over the duration of drug release, thereby making small molecules—and even peptides—cost effective for the companion and food animal markets," said Dr. Alexandre Melin, Director of Animal Health for MedinCell. "Our platform's inherent flexibility enables us to design single-injection products that release drug molecules systemically over just a few days, or across multiple-months. With some APIs, we can achieve therapeutic plasma levels throughout an entire year," Dr. Melin (alexandre.melin@medincell.eu) continued.

Dr. Anh Nguyen, MedinCell Founder and CEO, explained, "MedinCell has experience formulating molecules for chemocastration, diabetes, pain control and parasitology. Our MedinGel™ technology brings a strong environmental benefit to animal health brands by reducing the required drug cargo, and therefore the amount of API cleared by the animals. This can also lead to a substantial reduction in product cost for animal health companies."

"MedinCell recognizes that the demand for protein production is increasing, and requires novel approaches to support the growing global population," commented Dr. Melin, who welcomes meeting requests at the World Animal Health Congress to discuss controlled-release strategies. "We look forward to designing novel products that improve product efficiency and animal treatment for the food animal industry," concluded Dr. Melin.

About MedinCell

MedinCell's patent-pending drug delivery technology, MedinGel, entraps drug molecules in a polymer matrix after injected. By limiting the initial drug burst, MedinCell can design formulations that extend release duration. With MedinGel, substantially less API cargo is required than for products designed for oral administration, which is a pivotal consideration for cost-sensitive markets such as animal health. MedinCell SA is headquartered in Montpellier, France, and recently launched formulation and R&D activities at its US subsidiary, MedinCell Corporation, in San Diego, California. Contact information for both facilities is available at www.medincell.com.

Information on the Terrapinn World Animal Health Congress is available online: http://www.terrapinn.com/2011/world-animal-health-congress/index.stm

 

 

CONTACT:  Chris Hoover, MedinCell Corporation, +1-858-216-4573, chris.hoover@medincell.com


'/>"/>
SOURCE MedinCell
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
4. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
5. Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
6. Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis
7. Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management
8. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
9. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
10. Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
11. Retrospective Analysis Explores LYSTEDA®s Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... According to the Webster’s dictionary, a hippie is defined as ... one company is going against the norm with a line of all-natural skincare that’s ... the green space is proud to announce its latest retail partnership with the Vitamin ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... weekend to host their second pop-up shop for three consecutive weekends. The pop-up ... to the Santa Barbara community, a community full of women who appreciate the ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... been hired as FluidEdge’s Vice President of Business Intelligence and Informatics, effective immediately. ... has demonstrated success leading teams as a healthcare business and financial strategist for ...
(Date:5/25/2016)... ... ... The United States Food and Drug Administration (FDA) has now cleared Capillus® laser ... the company is the first and only manufacturer of low level laser therapy (LLLT) ... , “This new level of clearance substantiates what many physicians have experienced firsthand ...
(Date:5/25/2016)... Pembroke Pines, FL (PRWEB) , ... ... ... Hospital West has received the American Heart Association/American Stroke Association's Get With ... Plus designation. , This achievement, a second for Memorial Healthcare System, ...
Breaking Medicine News(10 mins):